Business
IBT_B: Significant 27% mortality reduction observed in preterm infants, despite missed primary endpoints
IBT_B: Significant 27% mortality reduction observed in preterm infants, despite missed primary endpoints
About this update from Infant Bacterial Therapeutics Ab Class B
A large study in premature infants showed no statistical significance for primary endpoints (NEC and feeding tolerance), but demonstrated a significant 27% reduction in all-cause mortality with a strong safety profile. Regulatory submission is planned, leveraging the robust mortality benefit and existing precedents for approval based on secondary endpoints.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
View stock analysis, news, and events for Infant Bacterial Therapeutics Ab Class B